Ainos (NASDAQ:AIMD) Issues Earnings Results

Ainos (NASDAQ:AIMD) posted its quarterly earnings data on Thursday. The company reported ($0.64) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.00 million during the quarter.

Ainos Stock Down 11.6%

NASDAQ AIMD traded down $0.30 during trading on Friday, reaching $2.28. 59,804 shares of the company’s stock were exchanged, compared to its average volume of 733,522. Ainos has a 1 year low of $2.00 and a 1 year high of $5.00. The stock has a market cap of $10.88 million, a P/E ratio of -0.46 and a beta of 2.22. The company has a 50 day moving average price of $3.53 and a two-hundred day moving average price of $3.17. The company has a debt-to-equity ratio of 0.96, a quick ratio of 2.61 and a current ratio of 2.88.

Analyst Ratings Changes

A number of research firms have recently issued reports on AIMD. Wall Street Zen upgraded shares of Ainos from a “sell” rating to a “hold” rating in a report on Friday, September 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ainos in a report on Wednesday, November 5th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Insider Buying and Selling

In related news, major shareholder Carbon Nano Technology Taiwan sold 7,000 shares of the stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $3.59, for a total transaction of $25,130.00. Following the completion of the sale, the insider owned 1,037,206 shares of the company’s stock, valued at approximately $3,723,569.54. This represents a 0.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 9.79% of the company’s stock.

Institutional Trading of Ainos

A hedge fund recently bought a new stake in Ainos stock. Two Sigma Investments LP acquired a new position in Ainos, Inc. (NASDAQ:AIMD) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 23,008 shares of the company’s stock, valued at approximately $80,000. Two Sigma Investments LP owned approximately 0.48% of Ainos as of its most recent filing with the Securities and Exchange Commission (SEC).

About Ainos

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.